Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Devashri Mukherjee

Devashri Mukherjee

Decision Resources Group, India

Title: The global burden of atopic dermatitis

Biography

Biography: Devashri Mukherjee

Abstract

At Decision Resources Group, we specialize in forecasting trends in the global burden of diseases bolstered by extensive and comprehensive literature review. Atopic dermatitis, an inflammatory disease characterized by intense itching and eczematous lesions has become a common health problem affecting about 20% of children and 3% of adults worldwide. We base our report on the internationally accepted ISAAC Phase III results to which we retrofitted curves looking at historical data and developed a robust model to generate age and gender wise prevalence estimates for all ages. This model accounted for spontaneous remission as well as the birth cohort effect, which is the observed higher disease risk in children than adults. The ISAAC study results capture a uniform disease definition across all countries in our global estimates and allow for defensible and comparable rates of 12-month prevalence, lifetime prevalence and drug treatable population which we present across the North and South American, European, Asia Pacific, Middle East and African regions. We provide a snapshot of the worldwide prevalence indicating a worrisome rise in the low income countries but almost plateauing in the high income countries. Our report highlights the variation amongst the population eligible for drug treatment between high and low income countries. We also report the distribution of the disease based on its severity and atopic association. Combined with our ten year forecast, our results facilitate identification of countries at risk and enablement of opportunities for affordable promising therapies in those vulnerable countries.